Shiga T, Noguchi T, Nishimaki K, Kudo M
Dept. of Surgery, Shinshu University School of Medicine.
Gan To Kagaku Ryoho. 1989 Aug;16(8 Pt 2):2765-8.
From 1976 to 1988, hepatic arterial infusion chemotherapy was performed in 52 patients with unresectable hepato-cellular carcinomas. Forty-nine (94%) out of 52 patients were stage III or stage IV. Thirty-five patients underwent continuous infusion of 5-FU and MMC employing chronometric infusion pumps. Mean survival of this group was 9 months. Six patients survived more than 12 months; the longest survivor died of different causes 40 months after surgery. Another patient lived for 30 months. In 10 patients, hepatic arterial ligation was performed in combination with infusion chemotherapy in the hepatic artery. Mean survival of these patients was 14 months. Four out of the 10 patients survived over 12 months. Recently, in 7 patients whose liver tumors were less than 4 cm in diameter and/or whose tumors were multiple and had liver disfunction, ethanol injection into the tumors during laparotomy was performed in combination with hepatic arterial infusion chemotherapy. In these 7 patients, an injection port system was implanted subcutaneously for intermittent infusion chemotherapy of MMC + 5-FU and ADM + lipiodol. Mean survival in this group was 14 months. One of 7 patients died 21 months after operation, but the others are alive at this writing. Five of these 6 patients have survived more than 12 months. AFP levels decreased in 3 patients after these treatments. In one case, AFP decreased to normal range for 18 months. These results suggested that intraoperative ethanol injection therapy into the tumors combining with hepatic arterial infusion chemotherapy may be of value for unresectable smaller liver carcinomas, since this method is technically easy and can assure injection of ethanol into the tumors during laparotomy.
1976年至1988年期间,对52例无法切除的肝细胞癌患者进行了肝动脉灌注化疗。52例患者中有49例(94%)为Ⅲ期或Ⅳ期。35例患者使用计时输液泵持续输注5-氟尿嘧啶和丝裂霉素。该组患者的平均生存期为9个月。6例患者存活超过12个月;最长存活者在手术后40个月因不同原因死亡。另1例患者存活了30个月。10例患者在肝动脉灌注化疗的同时进行了肝动脉结扎。这些患者的平均生存期为14个月。10例患者中有4例存活超过12个月。最近,对7例肝肿瘤直径小于4 cm和/或肿瘤为多发且有肝功能障碍的患者,在剖腹手术期间将乙醇注射到肿瘤内,并联合肝动脉灌注化疗。在这7例患者中,皮下植入了一个注射端口系统,用于间歇性输注丝裂霉素+5-氟尿嘧啶和阿霉素+碘油进行化疗。该组患者的平均生存期为14个月。7例患者中有1例在术后21个月死亡,但其他患者在撰写本文时仍存活。这6例患者中有5例存活超过12个月。3例患者经这些治疗后甲胎蛋白水平下降。在1例患者中,甲胎蛋白降至正常范围并持续了18个月。这些结果表明,术中肿瘤内注射乙醇疗法联合肝动脉灌注化疗可能对无法切除的较小肝癌有价值,因为该方法技术上简单,且能确保在剖腹手术期间将乙醇注射到肿瘤内。